Navigation Links
Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
Date:4/22/2008

LDL, Non-HDL and apoB measurement helps physicians guide therapy for

cardiometabolic risk patients

BIRMINGHAM, Ala., April 22 /PRNewswire/ -- The determination of LDL, non-HDL and apoB are now recognized as valid, accurate and recommended methods of guiding and achieving the best treatment goals for patients with cardiometabolic risk (CMR). The VAP(R) Cholesterol Test (Atherotech, Inc.) is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by recent expert consensus guidelines (ADA-ACC).

Patients with Type 2 diabetes are at increased risk of CMR and cardiovascular disease due to several factors, including lipoprotein abnormalities identified through cholesterol testing. Because many patients with CMR (including Type 2 diabetics) have relatively normal levels of LDL, the American Diabetes Association (ADA) convened a consensus conference in association with the American College of Cardiology (ACC) and has issued updated guidelines for the measurement of lipoproteins such as LDL, HDL, non-HDL and apoB in CMR patients.

"Doctors treating patients with cardiometabolic risk now have clear guidelines to follow, including specific treatment targets for non-HDL and apoB that are individualized to the magnitude of risk," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The VAP Test is the only comprehensive lipid profile out there that routinely addresses and is compliant with both existing NCEP ATP III guidelines and the new ADA-ACC consensus statement."

The consensus statement confirms the importance of apoB, articulates its relationship to non-HDL and gives specific recommendations on treatment targets and managing residual risk. In addition to supporting existing (National Institutes of Health) NIH guidelines for LDL measurement and treatment, the ADA-ACC consensus panel recommends the calculation of non-HDL cholesterol on all lab reports to determine cardiovascular disease risk in CMR patients with low to moderate LDL levels and the calculation of apoB in patients with CMR who are on medication. As published in Diabetes Care, the ADA-ACC consensus document also acknowledges the value of directly measured LDL levels when triglyceride levels exceed 200, a frequent occurrence in CMR patients. Extending beyond previous guidelines to specifically address the issue of cardiometabolic risk, the new statement advises clinicians to measure and treat apoB to goal: apoB below 80 (mg/dl) for the highest risk patients or apoB below 90 for high risk patients.

Of note is the fact that the consensus document experts specifically favor apoB, which is considered internationally as the "best reflection of atherogenic particle burden" and does not currently recommend the measurement of nuclear magnetic resonance (NMR) derived LDL-P primarily because of a dearth of clinical evidence and questions about its validity among various ethnic groups. The report also acknowledges that more aggressive control of other lipoprotein parameters may be warranted in those with high concentrations of Lp(a), a particle that is measured in all VAP samples.

The VAP (Vertical Auto Profile) Test is the most accurate and comprehensive cholesterol test available today, reporting 15 separate components of blood cholesterol as opposed to four in a standard test, and is the only cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes.

The VAP Test provides physicians with direct measurement of LDL, HDL, and all clinically relevant subclasses, and includes non-HDL, a highly accurate determination of apo B, emerging risk factors (such as Lp(a), LDL pattern, density and size) and precise calculations for LDL components. The test helps to clearly identify individuals with cardiometabolic risk and is able to identify far more patients at risk for heart disease than the standard cholesterol test.

The VAP Test is available nationwide. For more information visit http://www.thevaptest.com or call 877-901-8510.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP Technology. The VAP Test directly measures the cholesterol content of all lipids, components and subclasses. It is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations calling for more accurate, direct low-density lipoprotein (LDL) measurement, which is unaffected by triglycerides. The VAP Cholesterol Test -- the new standard of care for patients at risk for cardiovascular disease -- is available through national and regional diagnostic laboratories and is reimbursed by most payers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
2. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
3. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
7. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
8. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
9. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling ... (CSO) that provides biopharma companies the experience, expertise, ... and deploy outsourced sales teams. Created in concert ... addresses both the strategic and tactical needs of ... sales solutions through both personal and non-personal promotion. ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols and ... from around the world. , The new GSCG clinic is headed by ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
Breaking Biology Technology:
(Date:2/3/2016)... LIVERMORE, Calif. , Feb. 3, 2016 ... Police Department in Missouri ... of license plate reader (LPR) data from Vigilant Solutions. ... a hit-and-run case in which the victim was walking out ... a parking space next to his vehicle, striking his ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
Breaking Biology News(10 mins):